Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$1,179 Mln
Revenue (TTM)
$655 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.4 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
3.9
Industry P/E
--
EV/EBITDA
-6.9
Div. Yield
0 %
Debt to Equity
0.9
Book Value
$3.1
EPS
$-1.2
Face value
--
Shares outstanding
113,794,396
CFO
$-150.74 Mln
EBITDA
$-596.71 Mln
Net Profit
$-794.68 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Novocure (NVCR)
| -18.4 | -22.8 | -18.4 | -39.8 | -44.0 | -39.8 | -2.9 |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|
|
Novocure (NVCR)
| -56.6 | -79.6 | -2.3 | -56.6 | 105.3 | 151.7 |
|
S&P Small-Cap 600
| 4.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China,... and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland. Address: Neuhofstrasse 21, Baar, Switzerland, 6340 Read more
Executive Chairman
Mr. William F. Doyle
Executive Chairman
Mr. William F. Doyle
Headquarters
Baar
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Novocure Ltd (NVCR) is $10.55 (NASDAQ) as of 02-Apr-2026 19:28 EDT. Novocure Ltd (NVCR) has given a return of -44.02% in the last 3 years.
Since, TTM earnings of Novocure Ltd (NVCR) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-10.58
|
4.23
|
|
2024
|
-19.06
|
8.92
|
|
2023
|
-7.71
|
4.41
|
|
2022
|
-83.25
|
17.46
|
|
2021
|
-133.67
|
19.00
|
The 52-week high and low of Novocure Ltd (NVCR) are Rs 20.06 and Rs 9.82 as of 04-Apr-2026.
Novocure Ltd (NVCR) has a market capitalisation of $ 1,179 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Novocure Ltd (NVCR), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-0.29
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.